Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal Prosiding University Research Colloquium
Nafa Umma
Universitas Muhammadiyah Magelang
Humanities Computer Science & IT Environmental Science Law, Crime, Criminology & Criminal Justice Medicine & Pharmacology

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
Exploring the Role of Progression Free Survival in Chemotherapy Protocol: A Literatur Review: Telaah Pustaka Penilaian Progression Free Survival Sebagai Parameter Klinis Tata Terapi Kanker Shyfa Anindya Padirja; Ngesti Rahayu; Tisa Fitria; Saniya Puspa Fasya; Nafa Umma; Salsabila Salma Zahrah; Setiyo Budi Santoso
Prosiding University Research Colloquium Proceeding of The 18th University Research Colloquium 2023: Bidang MIPA dan Kesehatan
Publisher : Konsorsium Lembaga Penelitian dan Pengabdian kepada Masyarakat Perguruan Tinggi Muhammadiyah 'Aisyiyah (PTMA) Koordinator Wilayah Jawa Tengah - DIY

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

Progression-Free Survival (PFS) measures cancer patients' resistance to tumor progression. This alternative measurement is effective in assessing the performance of cancer therapy protocols and may serve an evidence for evaluating the quality of life of patients and planning follow-up treatments. Here in, we review a number of PFS data publications for drugs used in cancer therapy. The review involves ten scientific articles met the inclusion criteria provided by the PubMed database. Our finding present the optimal performance of chemotherapy protocols in preventing disease progression in seven various cancer populations. The highest PFS values for each cancer such as: crizotinib for lung cancer (28.71 months), enzalutamide for prostate cancer (7.1 months), pamiparib for stomach cancer (3.7 months), anlotinib for liver cancer (4.2 months), irinotecan plus raltitrexed for esophageal cancer (3.91 months), folfoxiri plus bevacizumab for metastatic colorectal cancer (10.7 months), and paclitaxel plus vistusertib for ovarian carcinoma (4.5 months).
Co-Authors Ngesti Rahayu Salsabila Salma Zahrah Saniya Puspa Fasya Setiyo Budi Santoso Shyfa Anindya Padirja Tisa Fitria